Dupilumab for Atopic Dermatitis

"Data available on clinicaltrials.gov suggests that this medical trial is actively looking for participants. It was initially posted on August 9th 2022, and the information therein has been most recently modified as of September 29th 2022."

"That is accurate. Per the information found on clinicaltrials.gov, this investigation was first posted in August of 2022 and most recently updated on September 29th 2022; it is currently searching for 24 participants to be enrolled at a single medical facility."

"This scientific inquiry will measure its baseline efficacy by evaluating Homa IR. Secondary markers of success include systemic inflammatory biomarkers (IL1, TNFa, hs-CRP, MCP1, IL-6, IL-4 and IL13), adipokines (leptin and adiponectin) along with fasting free fatty acid levels to be evaluated during an OGTT."

"According to the inclusion criteria, this trial is available for individuals aged 18 to 60. Alternatively, there are 127 trials open specifically to patients under 18 and 257 other studies targeting those over 65 years old."

"This clinical trial requires 24 participants between the ages of 18 and 60 who have been diagnosed with insulin resistance. To be eligible, they must possess a BMI ranging from 22-29 kg/m^2, have taken dupilumab treatment for more than 6 months, or can verify that they used topical steroids or phototherapy to manage their Atopic dermatitis. Furthermore, all applicants are required to sign an informed consent form prior to enrollment."